## Jean-Pierre Pelletier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2361233/publications.pdf

Version: 2024-02-01

243 papers

20,262 citations

9428 76 h-index 135 g-index

245 all docs

245 docs citations

times ranked

245

14927 citing authors

#	Article	IF	Citations
1	The relationship between knee loading during gait and cartilage thickness in nontraumatic and posttraumatic knee osteoarthritis. Journal of Orthopaedic Research, 2022, 40, 1778-1786.	1.2	2
2	An Open Debate on the Morphological Measurement Methodologies of the Infrapatellar Fat Pad to Determine Its Association with the Osteoarthritis Process. Current Rheumatology Reports, 2022, 24, 76-80.	2.1	2
3	Estrogenic impregnation alters pain expression: analysis through functional neuropeptidomics in a surgical rat model of osteoarthritis. Naunyn-Schmiedeberg's Archives of Pharmacology, 2022, 395, 703-715.	1.4	4
4	Risk factors associated with the occurrence of total knee arthroplasty in patients with knee osteoarthritis: a nested case–control study. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210913.	1.2	1
5	A Machine Learning Model to Predict Knee Osteoarthritis Cartilage Volume Changes over Time Using Baseline Bone Curvature. Biomedicines, 2022, 10, 1247.	1.4	8
6	The association between change in bone marrow lesion size and change in tibiofemoral cartilage volume and knee symptoms. Rheumatology, 2021, 60, 2791-2800.	0.9	9
7	A warning machine learning algorithm for early knee osteoarthritis structural progressor patient screening. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2199325.	1.2	24
8	Associations of blood pressure and arterial stiffness with knee cartilage volume in patients with knee osteoarthritis. Rheumatology, 2021, 60, 4748-4754.	0.9	2
9	Osteoarthritis Research Society International (OARSI): Past, present and future. Osteoarthritis and Cartilage Open, 2021, 3, 100146.	0.9	1
10	Machine Learning–Based Individualized Survival Prediction Model for Total Knee Replacement in Osteoarthritis: Data From the Osteoarthritis Initiative. Arthritis Care and Research, 2021, 73, 1518-1527.	1.5	21
11	Common Biochemical and Magnetic Resonance Imaging Biomarkers of Early Knee Osteoarthritis and of Exercise/Training in Athletes: A Narrative Review. Diagnostics, 2021, 11, 1488.	1.3	4
12	Clinical relevance of MRI knee abnormalities in Australian rules football players: a longitudinal study. BMJ Open Sport and Exercise Medicine, 2021, 7, e001097.	1.4	0
13	Associations of Joint Line Tenderness and Patellofemoral Grind With Longâ€Term Knee Joint Outcomes: Data From the Osteoarthritis Initiative. Arthritis Care and Research, 2020, 72, 778-786.	1.5	3
14	The bulge sign – a simple physical examination for identifying progressive knee osteoarthritis: data from the Osteoarthritis Initiative. Rheumatology, 2020, 59, 1288-1295.	0.9	5
15	Mesenchymal Stromal Cell Immunology for Efficient and Safe Treatment of Osteoarthritis. Frontiers in Cell and Developmental Biology, 2020, 8, 567813.	1.8	21
16	Intra-articular corticosteroid knee injection induces a reduction in meniscal thickness with no treatment effect on cartilage volume: a case–control study. Scientific Reports, 2020, 10, 13789.	1.6	16
17	Identification of the most important features of knee osteoarthritis structural progressors using machine learning methods. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2093346.	1.2	25
18	A continuous data driven translational model to evaluate effectiveness of population-level health interventions: case study, smoking ban in public places on hospital admissions for acute coronary events. Journal of Translational Medicine, 2020, 18, 466.	1.8	4

#	Article	IF	Citations
19	Serum adipokines/related inflammatory factors and ratios as predictors of infrapatellar fat pad volume in osteoarthritis: Applying comprehensive machine learning approaches. Scientific Reports, 2020, 10, 9993.	1.6	13
20	An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein <i>vs</i> celecoxib on symptoms in knee osteoarthritis. Rheumatology, 2020, 59, 3858-3868.	0.9	26
21	A reliable time-series method for predicting arthritic disease outcomes: New step from regression toward a nonlinear artificial intelligence method. Computer Methods and Programs in Biomedicine, 2020, 189, 105315.	2.6	12
22	Role of Lipocalin‶ype Prostaglandin D Synthase in Experimental Osteoarthritis. Arthritis and Rheumatology, 2020, 72, 1524-1533.	2.9	8
23	Effect of Intravenous Zoledronic Acid on Tibiofemoral Cartilage Volume Among Patients With Knee Osteoarthritis With Bone Marrow Lesions. JAMA - Journal of the American Medical Association, 2020, 323, 1456.	3.8	59
24	Viewpoint on Time Series and Interrupted Time Series Optimum Modeling for Predicting Arthritic Disease Outcomes. Current Rheumatology Reports, 2020, 22, 27.	2.1	3
25	In vivo protective effect of adipsin-deficiency on spontaneous knee osteoarthritis in aging mice. Aging, 2020, 12, 2880-2896.	1.4	8
26	L-PGDS deficiency accelerated the development of naturally occurring age-related osteoarthritis. Aging, 2020, 12, 24778-24797.	1.4	7
27	Response to "Bio-optimized Curcuma longa extract is efficient on knee osteoarthritis pain: a double-blind multicenter randomized placebo controlled three-arm study― Arthritis Research and Therapy, 2020, 22, 22.	1.6	0
28	Activation of The Phosphatidylcholine to Lysophosphatidylcholine Pathway Is Associated with Osteoarthritis Knee Cartilage Volume Loss Over Time. Scientific Reports, 2019, 9, 9648.	1.6	34
29	Sensitivity of functional targeted neuropeptide evaluation in testing pregabalin analgesic efficacy in a rat model of osteoarthritis pain. Clinical and Experimental Pharmacology and Physiology, 2019, 46, 723-733.	0.9	3
30	An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Seminars in Arthritis and Rheumatism, 2019, 49, 337-350.	1.6	392
31	Knee effusion volume assessed by magnetic resonance imaging and progression of knee osteoarthritis: data from the Osteoarthritis Initiative. Rheumatology, 2019, 58, 246-253.	0.9	29
32	A new decision tree for diagnosis of osteoarthritis in primary care: international consensus of experts. Aging Clinical and Experimental Research, 2019, 31, 19-30.	1.4	31
33	Machine-learning-based patient-specific prediction models for knee osteoarthritis. Nature Reviews Rheumatology, 2019, 15, 49-60.	3.5	119
34	Osteoarthritic pain model influences functional outcomes and spinal neuropeptidomics: A pilot study in female rats. Canadian Journal of Veterinary Research, 2019, 83, 133-141.	0.2	4
35	Diacerein-containing products: same risk of diarrhoea?. Aging Clinical and Experimental Research, 2018, 30, 411-412.	1.4	12
36	In vivo effect of opticin deficiency in cartilage in a surgically induced mouse model of osteoarthritis. Scientific Reports, 2018, 8, 457.	1.6	8

#	Article	IF	Citations
37	How Do MRI-Detected Subchondral Bone Marrow Lesions (BMLs) on Two Different MRI Sequences Correlate with Clinically Important Outcomes?. Calcified Tissue International, 2018, 103, 131-143.	1.5	3
38	Validity of Combining History Elements and Physical Examination Tests to Diagnose Patellofemoral Pain. Archives of Physical Medicine and Rehabilitation, 2018, 99, 607-614.e1.	0.5	15
39	Exploring determinants predicting response to intra-articular hyaluronic acid treatment in symptomatic knee osteoarthritis: 9-year follow-up data from the Osteoarthritis Initiative. Arthritis Research and Therapy, 2018, 20, 40.	1.6	18
40	Reply. Arthritis Care and Research, 2018, 70, 168-168.	1.5	1
41	Refinement of the Montreal Instrument for Cat Arthritis Testing, for Use by Veterinarians: detection of naturally occurring osteoarthritis in laboratory cats. Journal of Feline Medicine and Surgery, 2018, 20, 728-740.	0.6	17
42	Diagnostic Validity of Combining History Elements and Physical Examination Tests for Traumatic and Degenerative Symptomatic Meniscal Tears. PM and R, 2018, 10, 472-482.	0.9	5
43	Knee pain as a predictor of structural progression over 4 years: data from the Osteoarthritis Initiative, a prospective cohort study. Arthritis Research and Therapy, 2018, 20, 250.	1.6	36
44	Initial derivation of diagnostic clusters combining history elements and physical examination tests for symptomatic knee osteoarthritis. Musculoskeletal Care, 2018, 16, 370-379.	0.6	2
45	Impact of oral osteoarthritis therapyÂusage among other risk factors on knee replacement: a nested case-control study using the Osteoarthritis Initiative cohort. Arthritis Research and Therapy, 2018, 20, 172.	1.6	16
46	Clinical diagnosis of partial or complete anterior cruciate ligament tears using patients' history elements and physical examination tests. PLoS ONE, 2018, 13, e0198797.	1.1	19
47	Peak vertical force in a stabilized canine cranial cruciate deficient stifle model: A one-year follow-up. Canadian Journal of Veterinary Research, 2018, 82, 159-161.	0.2	1
48	Spinal neuropeptide modulation, functional assessment and cartilage lesions in a monosodium iodoacetate rat model of osteoarthritis. Neuropeptides, 2017, 65, 56-62.	0.9	12
49	Bone curvature changes can predict the impact of treatment on cartilage volume loss in knee osteoarthritis: data from a 2-year clinical trial. Rheumatology, 2017, 56, 989-998.	0.9	11
50	Exacerbation of Agingâ€Associated and Instabilityâ€Induced Murine Osteoarthritis With Deletion of D Prostanoid Receptor 1, a Prostaglandin D <sub>2</sub> Receptor. Arthritis and Rheumatology, 2017, 69, 1784-1795.	2.9	11
51	Intra-articular hyaluronic acid in the treatment of knee osteoarthritis: a Canadian evidence-based perspective. Therapeutic Advances in Musculoskeletal Disease, 2017, 9, 231-246.	1.2	59
52	Levels of serum biomarkers from a two-year multicentre trial are associated with treatment response on knee osteoarthritis cartilage loss as assessed by magnetic resonance imaging: an exploratory study. Arthritis Research and Therapy, 2017, 19, 169.	1.6	30
53	Analgesic efficacy of tramadol in cats with naturally occurring osteoarthritis. PLoS ONE, 2017, 12, e0175565.	1.1	35
54	Analgesic efficacy of an oral transmucosal spray formulation of meloxicam alone or in combination with tramadol in cats with naturally occurring osteoarthritis. Veterinary Anaesthesia and Analgesia, 2016, 43, 643-651.	0.3	34

#	Article	IF	Citations
55	Longâ€Term Effects of Glucosamine and Chondroitin Sulfate on the Progression of Structural Changes in Knee Osteoarthritis: Sixâ€Year Followup Data From the Osteoarthritis Initiative. Arthritis Care and Research, 2016, 68, 1560-1566.	1.5	30
56	Correlation Between Changes in Global Knee Structures Assessed by Magnetic Resonance Imaging and Radiographic Osteoarthritis Changes Over Ten Years in a Midlife Cohort. Arthritis Care and Research, 2016, 68, 958-964.	1.5	7
57	Measuring Disease Progression in Osteoarthritis. Current Treatment Options in Rheumatology, 2016, 2, 97-110.	0.6	10
58	Concurrent validity of different functional and neuroproteomic pain assessment methods in the rat osteoarthritis monosodium iodoacetate (MIA) model. Arthritis Research and Therapy, 2016, 18, 150.	1.6	26
59	Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study. Arthritis Research and Therapy, 2016, 18, 256.	1.6	38
60	Osteoarthritis. Nature Reviews Disease Primers, 2016, 2, 16072.	18.1	1,011
61	Does cartilage volume measurement or radiographic osteoarthritis at baseline independently predict ten-year cartilage volume loss?. BMC Musculoskeletal Disorders, 2016, 17, 54.	0.8	6
62	Natural history and clinical significance of meniscal tears over 8Âyears in a midlife cohort. BMC Musculoskeletal Disorders, 2016, 17, 4.	0.8	20
63	Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Annals of the Rheumatic Diseases, 2016, 75, 37-44.	0.5	194
64	Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Seminars in Arthritis and Rheumatism, 2016, 45, S22-S27.	1.6	101
65	Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. Drugs and Aging, 2016, 33, 75-85.	1.3	116
66	A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis—From evidence-based medicine to the real-life setting. Seminars in Arthritis and Rheumatism, 2016, 45, S3-S11.	1.6	203
67	The levels of the adipokines adipsin and leptin are associated with knee osteoarthritis progression as assessed by MRI and incidence of total knee replacement in symptomatic osteoarthritis patients: a <i>post hoc</i> analysis. Rheumatology, 2016, 55, 680-688.	0.9	51
68	Efficacy and safety of topical NSAIDs in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Seminars in Arthritis and Rheumatism, 2016, 45, S18-S21.	1.6	157
69	Animal models of osteoarthritis. , 2015, , 1454-1461.		4
70	Magnetic Resonance Imaging–Assessed Vastus Medialis Muscle Fat Content and Risk for Knee Osteoarthritis Progression: Relevance From a Clinical Trial. Arthritis Care and Research, 2015, 67, 1406-1415.	1.5	26
71	Discrepancies in Composition and Biological Effects of Different Formulations of Chondroitin Sulfate. Molecules, 2015, 20, 4277-4289.	1.7	84
72	History of knee injury and MRI-assessed knee structures in middle- and older-aged adults: a cross-sectional study. Clinical Rheumatology, 2015, 34, 1463-1472.	1.0	4

#	Article	IF	CITATIONS
73	Meniscal extrusion promotes knee osteoarthritis structural progression: protective effect of strontium ranelate treatment in a phase III clinical trial. Arthritis Research and Therapy, 2015, 17, 82.	1.6	25
74	Response to:  Concerns about report suggesting glucosamine and chondroitin protect against cartilage loss' by Felson. Annals of the Rheumatic Diseases, 2015, 74, e39-e39.	0.5	0
75	PPARÎ <sup>3</sup> deficiency results in severe, accelerated osteoarthritis associated with aberrant mTOR signalling in the articular cartilage. Annals of the Rheumatic Diseases, 2015, 74, 569-578.	0.5	186
76	Disease-modifying effect of strontium ranelate in a subset of patients from the Phase III knee osteoarthritis study SEKOIA using quantitative MRI: reduction in bone marrow lesions protects against cartilage loss. Annals of the Rheumatic Diseases, 2015, 74, 422-429.	0.5	106
77	Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and Frailty. Drugs and Aging, 2015, 32, 525-535.	1.3	31
78	Impact of disease treatments on the progression of knee osteoarthritis structural changes related to meniscal extrusion: Data from the OAI progression cohort. Seminars in Arthritis and Rheumatism, 2015, 45, 257-267.	1.6	21
79	[18F]-fluorodeoxyglucose positron emission tomography of the cat brain: A feasibility study to investigate osteoarthritis-associated pain. Veterinary Journal, 2015, 204, 299-303.	0.6	19
80	Drug/Agent Treatments for Osteoarthritis: Present and Future. , 2015, , 191-210.		3
81	Coxofemoral joint kinematics using video fluoroscopic images of treadmill-walking cats: development of a technique to assess osteoarthritis-associated disability. Journal of Feline Medicine and Surgery, 2015, 17, 134-143.	0.6	4
82	Cartilage-specific deletion of mTOR upregulates autophagy and protects mice from osteoarthritis. Annals of the Rheumatic Diseases, 2015, 74, 1432-1440.	0.5	322
83	First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24â€months: data from the osteoarthritis initiative progression cohort. Annals of the Rheumatic Diseases, 2015, 74, 547-556.	0.5	81
84	The presence of meniscal lesions is a strong predictor of neuropathic pain in symptomatic knee osteoarthritis: a cross-sectional pilot study. Arthritis Research and Therapy, 2014, 16, 507.	1.6	50
85	Responsiveness of Magnetic Resonance Imaging-derived Measures Over 2.7 Years. Journal of Rheumatology, 2014, 41, 2060-2067.	1.0	8
86	An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism, 2014, 44, 253-263.	1.6	414
87	A medicinal herb-based natural health product improves the condition of a canine natural osteoarthritis model: A randomized placebo-controlled trial. Research in Veterinary Science, 2014, 97, 574-581.	0.9	19
88	Association between sensitisation and pain-related behaviours in an experimental canine model of osteoarthritis. Pain, 2014, 155, 2071-2079.	2.0	10
89	Evoked Temporal Summation in Cats to Highlight Central Sensitization Related to Osteoarthritis-Associated Chronic Pain: A Preliminary Study. PLoS ONE, 2014, 9, e97347.	1.1	26
90	Health economics in the field of osteoarthritis: An Expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism, 2013, 43, 303-313.	1.6	239

#	Article	IF	CITATIONS
91	New and emerging treatments for osteoarthritis management: will the dream come true with personalized medicine?. Expert Opinion on Pharmacotherapy, 2013, 14, 2059-2077.	0.9	24
92	Total Knee Replacement as a Knee Osteoarthritis Outcome. Cartilage, 2013, 4, 219-226.	1.4	29
93	Adult Cartilage-Specific Peroxisome Proliferator–Activated Receptor Gamma Knockout Mice Exhibit the Spontaneous Osteoarthritis Phenotype. American Journal of Pathology, 2013, 182, 1099-1106.	1.9	63
94	Strontium ranelate reduces the progression of experimental dog osteoarthritis by inhibiting the expression of key proteases in cartilage and of IL- $1\hat{l}^2$ in the synovium. Annals of the Rheumatic Diseases, 2013, 72, 250-257.	0.5	68
95	A Posteriori Comparison of Natural and Surgical Destabilization Models of Canine Osteoarthritis. BioMed Research International, 2013, 2013, 1-12.	0.9	30
96	Assessment of Cartilage Changes Over Time in Knee Osteoarthritis Diseaseâ€Modifying Osteoarthritis Drug Trials Using Semiquantitative and Quantitative Methods: Pros and Cons. Arthritis Care and Research, 2013, 65, 686-694.	1.5	24
97	Expression of Peroxisome Proliferator-activated Receptors $\hat{l}\pm$ , $\hat{l}^2$ , $\hat{l}^3$ , and H- and L-Prostaglandin D Synthase During Osteoarthritis in the Spontaneous Hartley Guinea Pig and Experimental Dog Models. Journal of Rheumatology, 2013, 40, 877-890.	1.0	17
98	Reliability and sensitivity to change of IW-TSE versus DESS magnetic resonance imaging sequences in the assessment of bone marrow lesions in knee osteoarthritis patients: Longitudinal data from the Osteoarthritis Initiative (OAI) cohort. Journal of Biomedical Science and Engineering, 2013, 06, 337-345.	0.2	5
99	<i>Brachystemma calycinum</i> D. Don Effectively Reduces the Locomotor Disability in Dogs with Naturally Occurring Osteoarthritis: A Randomized Placebo-Controlled Trial. Evidence-based Complementary and Alternative Medicine, 2012, 2012, 1-9.	0.5	12
100	Influence of Tumor Necrosis Factor $\hat{l}_{\pm}$ , Parathyroid Hormone, and Vitamin D <sub>3</sub> on Modulation of the RANKL2 Isoform. Cartilage, 2012, 3, 100-103.	1.4	1
101	In vivo boneâ€specific EphB4 overexpression in mice protects both subchondral bone and cartilage during osteoarthritis. Arthritis and Rheumatism, 2012, 64, 3614-3625.	6.7	31
102	Future therapeutics for osteoarthritis. Bone, 2012, 51, 297-311.	1.4	93
103	Clinical validity of outcome pain measures in naturally occurring canine osteoarthritis. BMC Veterinary Research, 2012, 8, 162.	0.7	42
104	Egr-1 contributes to IL-1-mediated down-regulation of peroxisome proliferator-activated receptor $\hat{l}^3$ expression in human osteoarthritic chondrocytes. Arthritis Research and Therapy, 2012, 14, R69.	1.6	25
105	A fully automated system for quantification of knee bone marrow lesions using MRI and the osteoarthritis initiative cohort. Journal of Biomedical Graphics and Computing, 2012, 3, .	0.2	6
106	Egrâ€1 mediates the suppressive effect of ILâ€1 on PPARg expression in human OA chondrocytes. FASEB Journal, 2012, 26, lb80.	0.2	0
107	Peroxisome proliferator-activated receptor gamma in osteoarthritis. Modern Rheumatology, 2011, 21, 1-9.	0.9	57
108	Risk factors predictive of joint replacement in a 2-year multicentre clinical trial in knee osteoarthritis using MRI: results from over 6 years of observation. Annals of the Rheumatic Diseases, 2011, 70, 1382-1388.	0.5	93

#	Article	IF	CITATIONS
109	Tiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament model. Arthritis Research and Therapy, 2011, 13, R98.	1.6	86
110	Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nature Reviews Rheumatology, 2011, 7, 33-42.	3.5	1,973
111	Strontium ranelate inhibits key factors affecting bone remodeling in human osteoarthritic subchondral bone osteoblasts. Bone, 2011, 49, 559-567.	1.4	103
112	A fully automated human knee 3D MRI bone segmentation using the ray casting technique. Medical and Biological Engineering and Computing, 2011, 49, 1413-1424.	1.6	49
113	Treatment with Tiludronic Acid Helps Reduce the Development of Experimental Osteoarthritis Lesions in Dogs with Anterior Cruciate Ligament Transection Followed by Reconstructive Surgery: A 1-Year Study with Quantitative Magnetic Resonance Imaging. Journal of Rheumatology, 2011, 38, 118-128.	1.0	20
114	Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Annals of the Rheumatic Diseases, 2011, 70, 982-989.	0.5	164
115	Proteinase-activated Receptor-2 Gene Disruption Limits the Effect of Osteoarthritis on Cartilage in Mice: A Novel Target in Joint Degradation. Journal of Rheumatology, 2011, 38, 911-920.	1.0	30
116	Peroxisome proliferator-activated receptor gamma in osteoarthritis. Modern Rheumatology, 2011, 21, 1-9.	0.9	46
117	Animal models of osteoarthritis., 2011, , 1731-1739.e2.		3
118	Valproic acid suppresses interleukinâ€1βâ€induced microsomal prostaglandin E2 Synthaseâ€1 expression in chondrocytes. FASEB Journal, 2011, 25, 945.14.	0.2	0
119	Prostaglandin D2 enhances interleukin â€1βâ€induced cyclooxygenaseâ€2 expression in osteoarthritic cartilage. FASEB Journal, 2011, 25, 945.15.	0.2	0
120	Interleukinâ€1â€induced cyclooxygenaseâ€2 and inducible nitric oxide synthase expression in human OA chondrocytes is associated with histone H3K4 methylation. FASEB Journal, 2011, 25, 945.4.	0.2	0
121	Automatic Human Knee Cartilage Segmentation From 3-D Magnetic Resonance Images. IEEE Transactions on Biomedical Engineering, 2010, 57, 2699-2711.	2.5	98
122	An Open-Label Pilot Study Evaluating by Magnetic Resonance Imaging the Potential for a Disease-Modifying Effect of Celecoxib Compared to a Modelized Historical Control Cohort in the Treatment of Knee Osteoarthritis. Seminars in Arthritis and Rheumatism, 2010, 40, 185-192.	1.6	38
123	Targeting subchondral bone for treating osteoarthritis: what is the evidence?. Best Practice and Research in Clinical Rheumatology, 2010, 24, 51-70.	1.4	147
124	Experimental models of osteoarthritis: usefulness in the development of disease-modifying osteoarthritis drugs/agents. Therapy: Open Access in Clinical Medicine, 2010, 7, 621-634.	0.2	12
125	Relationship between bone marrow lesions, cartilage loss and pain in knee osteoarthritis: results from a randomised controlled clinical trial using MRI. Annals of the Rheumatic Diseases, 2010, 69, 2118-2124.	0.5	58
126	Bone marrow lesions in people with knee osteoarthritis predict progression of disease and joint replacement: a longitudinal study. Rheumatology, 2010, 49, 2413-2419.	0.9	178

#	Article	IF	CITATIONS
127	Variable Effects of 3 Different Chondroitin Sulfate Compounds on Human Osteoarthritic Cartilage/Chondrocytes: Relevance of Purity and Production Process. Journal of Rheumatology, 2010, 37, 656-664.	1.0	47
128	Meniscal extrusion predicts increases in subchondral bone marrow lesions and bone cysts and expansion of subchondral bone in osteoarthritic knees. Rheumatology, 2010, 49, 997-1004.	0.9	101
129	Oral treatment with a Brachystemma calycinum D don plant extract reduces disease symptoms and the development of cartilage lesions in experimental dog osteoarthritis: inhibition of protease-activated receptor 2. Annals of the Rheumatic Diseases, 2010, 69, 1179-1184.	0.5	13
130	Effects of diacerein at the molecular level in the osteoarthritis disease process. Therapeutic Advances in Musculoskeletal Disease, 2010, 2, 95-104.	1.2	79
131	Bone marrow lesions predict site-specific cartilage defect development and volume loss: a prospective study in older adults. Arthritis Research and Therapy, 2010, 12, R222.	1.6	96
132	Fully automated system for the quantification of human osteoarthritic knee joint effusion volume using magnetic resonance imaging. Arthritis Research and Therapy, 2010, 12, R173.	1.6	35
133	New Perspective in Osteoarthritis: The OPG and RANKL System as a Potential Therapeutic Target?. Keio Journal of Medicine, 2009, 58, 29-40.	0.5	90
134	Imaging in osteoarthritis trials: useful or just expensive?. Nature Clinical Practice Rheumatology, 2009, 5, 76-77.	3.2	2
135	Modulation of OPG, RANK and RANKL by human chondrocytes and their implication during osteoarthritis. Rheumatology, 2009, 48, 1482-1490.	0.9	99
136	Altered mineralization of human osteoarthritic osteoblasts is attributable to abnormal type I collagen production. Arthritis and Rheumatism, 2009, 60, 1438-1450.	6.7	130
137	Protective effects of total fraction of avocado/soybean unsaponifiables on the structural changes in experimental dog osteoarthritis: inhibition of nitric oxide synthase and matrix metalloproteinase-13. Arthritis Research and Therapy, 2009, 11, R41.	1.6	84
138	Human articular chondrocytes express 15-lipoxygenase-1 and -2: potential role in osteoarthritis. Arthritis Research and Therapy, 2009, 11, R44.	1.6	28
139	Increased expression of lipocalin-type prostaglandin D2 synthase in osteoarthritic cartilage. Arthritis Research and Therapy, 2009, 10, R146.	1.6	21
140	Proteinase-activated receptor (PAR)-2 activation impacts bone resorptive properties of human osteoarthritic subchondral bone osteoblasts. Bone, 2009, 44, 1143-1150.	1.4	34
141	Inhibition of interleukinâ $\in$ lî²â $\in$ "induced matrix metalloproteinases 1 and 13 production in human osteoarthritic chondrocytes by prostaglandin D <sub>2</sub> . Arthritis and Rheumatism, 2008, 58, 3530-3540.	6.7	53
142	Activation of the receptor EphB4 by its specific ligand ephrin B2 in human osteoarthritic subchondral bone osteoblasts. Arthritis and Rheumatism, 2008, 58, 3820-3830.	6.7	51
143	Osteophytosis, Subchondral Bone Sclerosis, Joint Effusion and Soft Tissue Thickening in Canine Experimental Stifle Osteoarthritis: Comparison Between 1.5ÂT Magnetic Resonance Imaging and Computed Radiography. Veterinary Surgery, 2008, 37, 166-177.	0.5	53
144	Cartilage in normal and osteoarthritis conditions. Best Practice and Research in Clinical Rheumatology, 2008, 22, 351-384.	1.4	424

#	Article	IF	CITATIONS
145	Analysis of the precision and sensitivity to change of different approaches to assess cartilage loss by quantitative MRI in a longitudinal multicentre clinical trial in knee osteoarthritis patients. Arthritis Research and Therapy, 2008, 10, R129.	1.6	34
146	Diacerein inhibits the synthesis of resorptive enzymes and reduces osteoclastic differentiation/survival in osteoarthritic subchondral bone: a possible mechanism for a protective effect against subchondral bone remodelling. Arthritis Research and Therapy, 2008, 10, R71.	1.6	51
147	Differential modulation of RANKL isoforms by human osteoarthritic subchondral bone osteoblasts: Influence of osteotropic factors. Bone, 2008, 43, 284-291.	1.4	55
148	Use of Quantitative Magnetic Resonance Imaging in the Cross-Sectional and Longitudinal Evaluation of Structural Changes in Knee Osteoarthritis Patients. , 2008, , 235-248.		2
149	Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study. Arthritis Research and Therapy, 2007, 9, R117.	1.6	90
150	Activation of proteinase-activated receptor 2 in human osteoarthritic cartilage upregulates catabolic and proinflammatory pathways capable of inducing cartilage degradation: a basic science study. Arthritis Research and Therapy, 2007, 9, R121.	1.6	61
151	Risk factors associated with the loss of cartilage volume on weight-bearing areas in knee osteoarthritis patients assessed by quantitative magnetic resonance imaging: a longitudinal study. Arthritis Research and Therapy, 2007, 9, R74.	1.6	204
152	Extracellular localization of galectin-3 has a deleterious role in joint tissues. Arthritis Research and Therapy, 2007, 9, R20.	1.6	38
153	The peroxisome proliferator–activated receptor γ agonist pioglitazone reduces the development of cartilage lesions in an experimental dog model of osteoarthritis: In vivo protective effects mediated through the inhibition of key signaling and catabolic pathways. Arthritis and Rheumatism, 2007, 56, 2288-2298.	6.7	68
154	Meniscal tear as an osteoarthritis risk factor in a largely non-osteoarthritic cohort: a cross-sectional study. Journal of Rheumatology, 2007, 34, 776-84.	1.0	115
155	DMOAD developments: present and future. Bulletin of the NYU Hospital for Joint Diseases, 2007, 65, 242-8.	0.7	27
156	Abnormal insulin-like growth factor 1 signaling in human osteoarthritic subchondral bone osteoblasts. Arthritis Research and Therapy, 2006, 8, R177.	1.6	42
157	Most recent developments in strategies to reduce the progression of structural changes in osteoarthritis: today and tomorrow. Arthritis Research and Therapy, 2006, 8, 206.	1.6	55
158	Modulation of insulin-like growth factor 1 levels in human osteoarthritic subchondral bone osteoblasts. Bone, 2006, 38, 333-341.	1.4	56
159	Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee:  Results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis and Rheumatism. 2006. 54. 3494-3507.	6.7	338
160	Licofelone reduces progression of structural changes in a canine model of osteoarthritis under curative conditions: effect on protease expression and activity. Journal of Rheumatology, 2006, 33, 1176-83.	1.0	16
161	Pioglitazone, a peroxisome proliferator-activated receptor? agonist, reduces the progression of experimental osteoarthritis in guinea pigs. Arthritis and Rheumatism, 2005, 52, 479-487.	6.7	104
162	Oral treatment with PD-0200347, an ?2? ligand, reduces the development of experimental osteoarthritis by inhibiting metalloproteinases and inducible nitric oxide synthase gene expression and synthesis in cartilage chondrocytes. Arthritis and Rheumatism, 2005, 52, 488-500.	6.7	59

#	Article	IF	CITATIONS
163	Osteoarthritis: A metabolic disease induced by local abnormal leptin activity?. Current Rheumatology Reports, 2005, 7, 1-3.	2.1	22
164	Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes. Arthritis Research and Therapy, 2005, 8, R21.	1.6	205
165	The protective effect of licofelone on experimental osteoarthritis is correlated with the downregulation of gene expression and protein synthesis of several major cartilage catabolic factors: MMP-13, cathepsin K and aggrecanases. Arthritis Research and Therapy, 2005, 7, R1091.	1.6	56
166	Leukotriene and prostaglandin synthesis pathways in osteoarthritic synovial membranes: regulating factors for interleukin 1beta synthesis. Journal of Rheumatology, 2005, 32, 704-12.	1.0	31
167	Activation of Peroxisome Proliferator-activated Receptor $\hat{l}^3$ Inhibits Interleukin- $1\hat{l}^2$ -induced Membrane-associated Prostaglandin E2 Synthase-1 Expression in Human Synovial Fibroblasts by Interfering with Egr-1. Journal of Biological Chemistry, 2004, 279, 22057-22065.	1.6	100
168	Rationale for the use of structure-modifying drugs and agents in the treatment of osteoarthritis. Osteoarthritis and Cartilage, 2004, 12, 63-68.	0.6	21
169	New Trends in the Treatment of Osteoarthritis. Seminars in Arthritis and Rheumatism, 2004, 34, 13-14.	1.6	5
170	Quantitative magnetic resonance imaging evaluation of knee osteoarthritis progression over two years and correlation with clinical symptoms and radiologic changes. Arthritis and Rheumatism, 2004, 50, 476-487.	6.7	235
171	Differential gene expression and regulation of the bone morphogenetic protein antagonists follistatin and gremlin in normal and osteoarthritic human chondrocytes and synovial fibroblasts. Arthritis and Rheumatism, 2004, 50, 2521-2530.	6.7	83
172	Regulation of the expression of 5-lipoxygenase-activating protein/5-lipoxygenase and the synthesis of leukotriene B4 in osteoarthritic chondrocytes: Role of transforming growth factor? and eicosanoids. Arthritis and Rheumatism, 2004, 50, 3925-3933.	6.7	56
173	The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K. Bone, 2004, 34, 527-538.	1.4	143
174	Computer-aided method for quantification of cartilage thickness and volume changes using mri: validation study using a synthetic model. IEEE Transactions on Biomedical Engineering, 2003, 50, 978-988.	2.5	134
175	Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: A randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism, 2003, 48, 370-377.	6.7	452
176	In vivo selective inhibition of mitogen-activated protein kinase kinase $1/2$ in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes. Arthritis and Rheumatism, 2003, 48, 1582-1593.	6.7	112
177	Oncostatin M: Foe or friend?. Arthritis and Rheumatism, 2003, 48, 3301-3303.	6.7	24
178	The Novartis-ILAR Rheumatology Prize 2001 Osteoarthritis: from molecule to man. Arthritis Research, 2002, 4, 13.	2.0	9
179	Study of the role of leukotriene B4 in abnormal function of human subchondral osteoarthritis osteoblasts: Effects of cyclooxygenase and/or 5-lipoxygenase inhibition. Arthritis and Rheumatism, 2002, 46, 1804-1812.	6.7	64
180	The in situ up-regulation of chondrocyte interleukin-1-converting enzyme and interleukin-18 levels in experimental osteoarthritis is mediated by nitric oxide. Arthritis and Rheumatism, 2002, 46, 2637-2647.	6.7	64

#	Article	IF	CITATIONS
181	PPARgamma ligands as modulators of inflammatory and catabolic responses in arthritis. An overview. Journal of Rheumatology, 2002, 29, 3-14.	1.0	182
182	Synthesis of interleukin 1beta, tumor necrosis factor-alpha, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants: interactions with antiinflammatory cytokines. Journal of Rheumatology, 2002, 29, 546-53.	1.0	52
183	Licofelone (ML-3000), a dual inhibitor of 5-lipoxygenase and cyclooxygenase, reduces the level of cartilage chondrocyte death in vivo in experimental dog osteoarthritis: inhibition of pro-apoptotic factors. Journal of Rheumatology, 2002, 29, 1446-53.	1.0	27
184	Metalloproteases and inhibitors in arthritic diseases. Best Practice and Research in Clinical Rheumatology, 2001, 15, 805-829.	1.4	233
185	Peroxisome proliferator-activated receptor? activators inhibit interleukin-1?-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes. Arthritis and Rheumatism, 2001, 44, 595-607.	6.7	196
186	Osteoarthritis, an inflammatory disease: Potential implication for the selection of new therapeutic targets. Arthritis and Rheumatism, 2001, 44, 1237-1247.	6.7	953
187	In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: Suppression of collagenase 1 and interleukin-1? synthesis. Arthritis and Rheumatism, 2001, 44, 2320-2330.	6.7	100
188	Endogenous Prostaglandin E2 and Insulin-like Growth Factor 1 Can Modulate the Levels of Parathyroid Hormone Receptor in Human Osteoarthritic Osteoblasts. Journal of Bone and Mineral Research, 2001, 16, 713-721.	3.1	59
189	Gene Therapy for Osteoarthritis. Clinical Orthopaedics and Related Research, 2000, 379, S262-S272.	0.7	17
190	Selective inhibition of inducible nitric oxide synthase reduces progression of experimental osteoarthritis in vivo: Possible link with the reduction in chondrocyte apoptosis and caspase 3 level. Arthritis and Rheumatism, 2000, 43, 1290-1299.	6.7	217
191	Efficacy and safety of diacerein in osteoarthritis of the knee: A double-blind, placebo-controlled trial. Arthritis and Rheumatism, 2000, 43, 2339-2348.	6.7	147
192	The Induction of Cell Death in Human Osteoarthritis Chondrocytes by Nitric Oxide Is Related to the Production of Prostaglandin E2 Via the Induction of Cyclooxygenase-2. Journal of Immunology, 2000, 165, 3402-3410.	0.4	171
193	The influence of tissular cross-talking on osteoarthritis progression: role of nonsteroidal antiinflammatory drugs. Osteoarthritis and Cartilage, 1999, 7, 306-307.	0.6	2
194	Subchondral bone morphological and biochemical alterations in osteoarthritis. Osteoarthritis and Cartilage, 1999, 7, 321-322.	0.6	48
195	Carprofen reduces the structural changes and the abnormal subchondral bone metabolism of experimental osteoarthritis. Osteoarthritis and Cartilage, 1999, 7, 327-328.	0.6	13
196	Collagenase 3 production by human osteoarthritic chondrocytes in response to growth factors and cytokines is a function of the physiologic state of the cells. Arthritis and Rheumatism, 1999, 42, 1147-1158.	6.7	82
197	Interleukin-1?-converting enzyme/caspase-1 in human osteoarthritic tissues: Localization and role in the maturation of interleukin-1? and interleukin-18. Arthritis and Rheumatism, 1999, 42, 1577-1587.	6.7	126
198	Abnormal regulation of urokinase plasminogen activator by insulin-like growth factor 1 in human osteoarthritic subchondral osteoblasts. Arthritis and Rheumatism, 1999, 42, 2112-2122.	6.7	58

#	Article	IF	CITATIONS
199	Mitogen-activated protein kinase and nuclear factor ?B together regulate interleukin-17-induced nitric oxide production in human osteoarthritic chondrocytes: Possible role of transactivating factor mitogen-activated protein kinase-activated protein kinase (MAPKAPK). Arthritis and Rheumatism, 1999, 42, 2399-2409.	6.7	152
200	In Vivo Transfer of Interleukin-1 Receptor Antagonist Gene in Osteoarthritic Rabbit Knee Joints. American Journal of Pathology, 1999, 154, 1159-1169.	1.9	218
201	Osteoblast-like cells from human subchondral osteoarthritic bone demonstrate an altered phenotype in vitro: Possible role in subchondral bone sclerosis. Arthritis and Rheumatism, 1998, 41, 891-899.	6.7	189
202	Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. Arthritis and Rheumatism, 1998, 41, 1275-1286.	6.7	318
203	Exercise protects against articular cartilage degeneration in the hamster. Arthritis and Rheumatism, 1998, 41, 2068-2076.	6.7	118
204	Transcriptional induction of cyclooxygenase-2 gene by okadaic acid inhibition of phosphatase activity in human chondrocytes: Co-stimulation of AP-1 and CRE nuclear binding proteins. Journal of Cellular Biochemistry, 1998, 69, 392-413.	1.2	81
205	Transcriptional induction of cyclooxygenaseâ€2 gene by okadaic acid inhibition of phosphatase activity in human chondrocytes: Coâ€stimulation of APâ€1 and CRE nuclear binding proteins. Journal of Cellular Biochemistry, 1998, 69, 392-413.	1.2	4
206	Exercise protects against articular cartilage degeneration in the hamster., 1998, 41, 2068.		1
207	Osteoarthritis of the Knee: Report of a Task Force of the International League of Associations for Rheumatology and the Osteoarthritis Research Society. Journal of the American Geriatrics Society, 1997, 45, 850-852.	1.3	4
208	Cloning, sequencing and characterization of the 5′-flanking region of the human collagenase-3 gene. Biochemical Journal, 1997, 323, 13-16.	1.7	63
209	Effects of tenidap on the progression of osteoarthritic lesions in a canine experimental model. Suppression of metalloprotease and interleukin-1 activity. Arthritis and Rheumatism, 1997, 40, 284-294.	6.7	28
210	In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis and Rheumatism, 1997, 40, 1012-1019.	6.7	353
211	Collagenase-3 (matrix metalloprotease 13) is preferentially localized in the deep layer of human arthritic cartilage in situ. In vitro mimicking effect by transforming growth factor $\hat{l}^2$ . Arthritis and Rheumatism, 1997, 40, 1653-1661.	6.7	163
212	MODULATION OF THE EXPRESSION OF GLUCOCORTICOID RECEPTORS IN SYNOVIAL FIBROBLASTS AND CHONDROCYTES BY PROSTAGLANDINS AND NSAIDs. American Journal of Therapeutics, 1996, 3, 115-119.	0.5	3
213	IGF and IGF-binding protein system in the synovial fluid of osteoarthritic and rheumatoid arthritic patients. Osteoarthritis and Cartilage, 1996, 4, 263-274.	0.6	63
214	The increased synthesis of inducible nitric oxide inhibits IL-1ra synthesis by human articular chondrocytes: possible role in osteoarthritic cartilage degradation. Osteoarthritis and Cartilage, 1996, 4, 77-84.	0.6	155
215	Tissue inhibitor of metalloproteinase-2 (TIMP-2) mRNA is constitutively expressed in bovine, human normal, and osteoarthritic articular chondrocytes., 1996, 60, 211-217.		40
216	Normal expression of type 1 insulin-like growth factor receptor by human osteoarthritic chondrocytes with increased expression and synthesis of insulin-like growth factor binding proteins. Arthritis and Rheumatism, 1996, 39, 968-978.	6.7	78

#	Article	IF	Citations
217	Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis and Rheumatism, 1996, 39, 1535-1544.	6.7	338
218	Increased insulin-like growth factor 1 production by human osteoarthritic chondrocytes is not dependent on growth hormone action. Arthritis and Rheumatism, 1995, 38, 413-419.	6.7	33
219	Effects of tenidap on canine experimental osteoarthritis i. morphologic and metalloprotease analysis. Arthritis and Rheumatism, 1995, 38, 1290-1303.	6.7	58
220	Interleukin- $1\hat{l}^2$ induction of tissue inhibitor of metalloproteinase (TIMP-1) is functionally antagonized by prostaglandin E2 in human synovial fibroblasts. Journal of Cellular Biochemistry, 1995, 57, 619-629.	1.2	18
221	Human Osteoarthritic Chondrocytes Possess an Increased Number of Insulin-Like Growth Factor 1 Binding Sites but are Unresponsive to its Stimulation. Arthritis and Rheumatism, 1994, 37, 253-263.	6.7	186
222	Intraarticular Injections with Methylprednisolone Acetate Reduce Osteoarthritic Lesions in Parallel with Chondrocyte Stromelysin Synthesis in Experimental Osteoarthritis. Arthritis and Rheumatism, 1994, 37, 414-423.	6.7	122
223	Transcriptional regulation of plasminogen activator inhibitor-1 expression in human synovial fibroblasts by prostaglandin E2: mediation by protein kinase A and role of interleukin-1. Molecular and Cellular Endocrinology, 1994, 103, 139-148.	1.6	12
224	Regulation of human normal and osteoarthritic chondrocyte interleukin-1 receptor by antirheumatic drugs. Arthritis and Rheumatism, 1993, 36, 1517-1527.	6.7	42
225	Effects of Nimesulide and Naproxen on the Degradation and Metalloprotease Synthesis of Human Osteoarthritic Cartilage. Drugs, 1993, 46, 34-39.	4.9	46
226	The synthesis of IL-1 receptor antagonist (IL-1ra) by synovial fibroblasts is markedly increased by the cytokines TNF-α and IL-1. Biochimica Et Biophysica Acta - Molecular Cell Research, 1993, 1175, 302-305.	1.9	28
227	In Vitro Effects of NSAIDS and Corticosteroids on the Synthesis and Secretion of Interleukin 1 by Human Osteoarthritic Synovial Membranes., 1993, 39, 181-193.		13
228	Expression of c-fos, c-jun,jun-B, metallothionein and metalloproteinase genes in human chondrocyte. FEBS Letters, 1992, 306, 169-172.	1.3	39
229	The interleukin-1 receptor in normal and osteoarthritic human articular chondrocytes. Identification as the type I receptor and analysis of binding kinetics and biologic function. Arthritis and Rheumatism, 1992, 35, 530-540.	6.7	151
230	Immunological analysis of proteoglycan structural changes in the early stage of experimental osteoarthritic canine cartilage lesions. Journal of Orthopaedic Research, 1992, 10, 511-523.	1.2	30
231	Synovial membrane histology and immunopathology in rheumatoid arthritis and osteoarthritis. In vivo effects of antirheumatic drugs. Arthritis and Rheumatism, 1991, 34, 153-163.	6.7	156
232	Glucocorticoid Receptor Mediated Inhibition of Interleukin-1 Stimulated Neutral Metalloprotease Synthesis in Normal Human Chondrocytes*. Journal of Clinical Endocrinology and Metabolism, 1991, 72, 316-326.	1.8	77
233	Imbalance between the mechanisms of activation and inhibition of metalloproteases in the early lesions of experimental osteoarthritis. Arthritis and Rheumatism, 1990, 33, 1466-1476.	6.7	126
234	Protective effects of corticosteroids on cartilage lesions and osteophyte formation in the pond-nuki dog model of osteoarthritis. Arthritis and Rheumatism, 1989, 32, 181-193.	6.7	156

#	Article	IF	CITATIONS
235	Human rheumatoid arthritic cartilage and its neutral proteoglycan-degrading proteases. The effects of antirheumatic drugs. Arthritis and Rheumatism, 1985, 28, 405-412.	6.7	23
236	Role of synovial membrane inflammation in cartilage matrix breakdown in the Pond-Nuki dog model of osteoarthritis. Arthritis and Rheumatism, 1985, 28, 554-561.	6.7	120
237	Cartilage degradation by neutral proteoglycanases in experimental osteoarthritis. Suppression by steroids. Arthritis and Rheumatism, 1985, 28, 1393-1401.	6.7	51
238	Ntp pyrophosphohydrolase in human chondrocalcinotic and osteoarthritic cartilage: some biochemical characteristic. Arthritis and Rheumatism, 1984, 27, 186-192.	6.7	38
239	Ntp pyrophosphohydrolase in human chondrocalcinotic and osteoarthritic cartilage: Further Studies on Histologic and Subcellular Distribution. Arthritis and Rheumatism, 1984, 27, 193-199.	6.7	56
240	Neutral proteases capable of proteoglycan digesting activity in osteoarthritic and normal human articular cartilage. Arthritis and Rheumatism, 1984, 27, 305-312.	6.7	156
241	Collagenase and collagenolytic activity in human osteoarthritic cartilage. Arthritis and Rheumatism, 1983, 26, 63-68.	6.7	152
242	Collagenolytic activity and collagen matrix breakdown of the articular cartilage in the pond-nuki dog model of osteoarthritis. Arthritis and Rheumatism, 1983, 26, 866-874.	6.7	124
243	Metalloproteases and Their Modulation as Treatment in Osteoarthritis. , 0, , 499-513.		4